Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma
Year: 2020
Type: article
Study design: Clinical Trial
Abstract: Tislelizumab, an anti-programmed death protein-1 (PD-1) monoclonal antibody, was engineered to minimize binding to the FcγR on macrophages to abrogate antibody-dependent phagocytosis, a mechanism of T-cell clearance and potential resistance to anti-PD-1 therapy. This single-arm phase 2 trial (NCT04004221/CTR20170071) assessed the safety, tolerability, and efficacy of tislelizumab in patients with PD-L1-positive urothelial carcinoma who progressed during/following platinum-containing therapy and had no prior PD-(L)1 inhibitor treatment. Patients were considered PD-L1 positive if ≥ 25% of tumor/immune cells expressed PD-L1 when using the VENTANA™ PD-L1 (SP263) assay. The primary endpoint was objective response rate by independent review committee. As of September 16, 2019, 113 patients had a median study follow-up time of 9.4 mo. Most patients (76%) had visceral metastases, including 24% with liver and 23% with bone metastases. Among 104 efficacy-evaluable patients, confirmed objective response rate was 24% (95% confidence interval, 16, 33), including 10 complete and 15 partial responses. Median duration of response was not reached. Among 25 responders, 17/25 (68%) had ongoing responses. Median progression-free survival and overall survival times were 2.1 and 9.8 mo, respectively. The most common treatment-related adverse events were anemia (27%) and pyrexia (19%). Anemia (7%) and hyponatremia (5%) were the only grade 3-4 treatment-related adverse events and occurred in ≥ 5% of patients. Three investigator-assessed deaths were considered to be possibly related to study treatment (hepatic failure, n = 2; respiratory arrest, n = 1). Tislelizumab demonstrated meaningful clinical benefits in patients with previously treated locally advanced or metastatic PD-L1-positive urothelial carcinoma and had a manageable safety profile.
Source: Cancer Science
DOI: 10.1111/cas.14681
Institutions: Fudan University, Fudan University Shanghai Cancer Center, Sichuan University, West China Medical Center of Sichuan University, West China Hospital of Sichuan University, Chinese Academy of Medical Sciences & Peking Union Medical College, Jiangsu Cancer Hospital, Peking Union Medical College Hospital, Liaoning Cancer Hospital & Institute, Second Hospital of Tianjin Medical University, Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Zhejiang Cancer Hospital, Peking University First Hospital, Peking University Third Hospital, Zhongshan Hospital, Anhui Provincial Hospital, Samsung Medical Center, Sungkyunkwan University, Zhejiang Provincial People's Hospital, BeiGene (China)
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,250
Funder: BeiGene
OpenAlex ID: W3092442011
